NJ biotech companies keep hiring; Lpath gets $3M grant;

 @FierceBiotech: NEJM lays out questions--and facts--about Provenge. Report | Follow @FierceBiotech

 @JohnCFierce: Genzyme breaks the $70 barrier on this morning's stories. Article | Follow @JohnCFierce

> The number of employees working at New Jersey biotechnology companies increased by 50 percent in the last three years, according to a survey conducted by BioNJ and Ernst & Young. Story

> Lpath was awarded a $3 million grant by the National Eye Institute's BRDG-SPAN Program to support Phase II clinical development of Lpath's iSONEP in treating exudative (or wet) AMD and possibly other ocular disorders. Lpath release

> B.C. should take Saskatchewan up on its invitation to help fund clinical trials of a controversial new treatment for multiple sclerosis, a provincial New Democrat says. News

> Singapore's position as a clinical research hub in the region is expected to be given a boost with the opening of a new clinical research unit. Report

> A London company may be on the verge of a groundbreaking treatment for diabetes--and an infusion of federal money announced yesterday in London may help it get there. Article

Special Report: Big Pharma's Q2 2010 Earnings Report. Report

And Finally... Hormonal contraceptives change the ways captive ring-tailed lemurs relate to one another both socially and sexually, according to a Duke University study that combined analyses of hormones, genes, scent chemicals and behavior. Report

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

Combining an anti-TREM2 antibody with an immuno-oncology drug that blocks PD-1 led to complete tumor control in a mouse study.